Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN.

× No keyword cloud information.

15 in total

1. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab.

Authors: K Matsuyama; N Ogata; M Matsuoka; M Wada; K Takahashi; T Nishimura
Journal: Br J Ophthalmol Date: 2010-06-10 Impact factor: 4.638

Review 2. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.

Authors: Vishal Ranpura; Sanjaykumar Hapani; Shenhong Wu
Journal: JAMA Date: 2011-02-02 Impact factor: 56.272

3. Cerebrovascular accidents in ranibizumab.

Authors: Takashi Ueta; Yasuo Yanagi; Yasuhiro Tamaki; Takuhiro Yamaguchi
Journal: Ophthalmology Date: 2009-02 Impact factor: 12.079

4. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.

Authors: Frank G Holz; Winfried Amoaku; Juan Donate; Robyn H Guymer; Ulrich Kellner; Reinier O Schlingemann; Andreas Weichselberger; Giovanni Staurenghi
Journal: Ophthalmology Date: 2011-04 Impact factor: 12.079

Review 5. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors: Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal: Am J Kidney Dis Date: 2007-02 Impact factor: 8.860

6. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors: Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal: N Engl J Med Date: 2011-04-28 Impact factor: 91.245

7. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.

Authors: David S Boyer; Jeffrey S Heier; David M Brown; Steven F Francom; Tsontcho Ianchulev; Roman G Rubio
Journal: Ophthalmology Date: 2009-07-29 Impact factor: 12.079

8. The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis?

Authors: C E Counsell; M J Clarke; J Slattery; P A Sandercock
Journal: BMJ Date: 1994 Dec 24-31

9. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors:
Journal: Lancet Date: 1988-08-13 Impact factor: 79.321

10. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Authors: Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves
Journal: Ophthalmology Date: 2012-05-11 Impact factor: 12.079

5 in total

Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN.

1. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab.

Review 2. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.

3. Cerebrovascular accidents in ranibizumab.

4. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.

Review 5. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

6. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

7. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.

8. The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis?

9. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

10. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Review 1. Intravitreal anti-VEGF agents and cardiovascular risk.

2. Storage stability of bevacizumab in polycarbonate and polypropylene syringes.

3. Bevacizumab for neovascular age-related macular degeneration in Chinese patients in a clinical setting.

Review 4. Principles of pharmacology in the eye.

Review 5. Aflibercept in wet AMD: specific role and optimal use.